What is the current febrile neutropenia market size?

The global febrile neutropenia market size was valued at approximately USD 1.8 billion in 2023, driven by rising cancer incidence and advanced treatment options.

What is the growth forecast for the febrile neutropenia market?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2030, supported by increasing adoption of prophylactic antibiotics and supportive care therapies.

What are the key drivers of the febrile neutropenia market?

Key drivers include rising cancer prevalence, higher use of chemotherapy, and growing awareness about infection prevention in immunocompromised patients.

What challenges does the febrile neutropenia market face?

Challenges include high treatment costs, drug resistance risks, and limited reimbursement coverage in emerging economies.

Which regions are leading the febrile neutropenia market?

North America dominates the market, while Europe and Asia-Pacific show high growth potential due to expanding healthcare infrastructure.

Who are the top companies in the febrile neutropenia market?

Leading companies include GSK, Roche, Merck & Co., and Takeda Pharmaceutical, focusing on innovation in antimicrobial and G-CSF therapies.

What are the future opportunities in the febrile neutropenia market?

Opportunities lie in personalized treatment protocols, biosimilar development, and expanding access to lower-income regions through partnerships.

How is technology impacting the febrile neutropenia market?

Advances in rapid diagnostic tools and AI-driven patient monitoring are improving early detection and management of febrile neutropenia cases.

What is the regulatory landscape for the febrile neutropenia market?

Regulatory bodies like the FDA and EMA emphasize safety and efficacy, with recent approvals focusing on reducing hospitalization and antibiotic overuse.

febrile neutropenia Growth Trends & Opportunity Analysis 2033

febrile neutropenia by Application (Hospitals, Clinics, Others), by Types (Pegfilgrastim, Vancomycin Hydrochloride, Filgrastim Biosimilars, Pegfilgrastim Biosimilars, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

febrile neutropenia Market Size | CAGR 12 Forecast 2033

febrile neutropenia Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

febrile neutropenia Market Overview

Febrile neutropenia (FN), a life-threatening complication of chemotherapy, drives demand for advanced diagnostics and therapeutics. The febrile neutropenia market size is projected to reach $1.35 billion by 2026, reflecting robust growth outlook and rising cancer incidence. This market forecast underscores the urgent need for rapid-acting antibiotics and granulocyte colony-stimulating factors (G-CSFs), fueling industry expansion across hospitals and oncology clinics globally.

Loading chart…

The febrile neutropenia market is expanding at a CAGR of 6.5% (2026–2033), driven by macro drivers such as aging populations, rising cancer prevalence, and approvals of biosimilar G-CSFs. Key forces reshaping the industry include technology shifts toward rapid diagnostic tests and regulatory tailwinds supporting cost-effective therapies. North America dominates the market due to high adoption of premium therapies, while the Asia-Pacific region emerges as the fastest-growing, propelled by expanding access to oncology care in China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.19 billion
Growth rate	CAGR of 12% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Xenetic Biosciences, Inc.; Richter Gedeon Nyrt.; Amgen Inc.; Hospira, Inc.; Eli Lilly and Company; USV Private Limited; Aequus BioPharma, Inc.; Taiho Pharmaceutical Co.,Ltd.; BeyondSpring Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of hematologic malignancies drives demand for febrile neutropenia market solutions, as chemotherapy-induced neutropenia remains a critical complication in oncology care. The global burden of diseases like leukemia and lymphoma is projected to increase, expanding the patient pool and boosting treatment adoption.

Advancements in supportive care therapies and febrile neutropenia market size growth are fueled by the launch of novel anti-infective agents and granulocyte colony-stimulating factors (G-CSF). These innovations enhance treatment efficacy and reduce hospitalization rates, aligning with value-based healthcare trends.

Restraints2 items

High treatment costs and limited reimbursement policies in emerging economies constrain febrile neutropenia market accessibility. Out-of-pocket expenses for advanced therapies remain a significant barrier for low-income patient populations.

Stringent regulatory requirements for drug approvals delay the commercialization of new therapies. Regulatory agencies emphasize robust clinical evidence, increasing development timelines and costs for market entrants.

Opportunities2 items

Expansion into untapped regional markets offers growth potential, particularly in Asia-Pacific and Latin America, where improving healthcare infrastructure and rising cancer awareness are expected to boost diagnostic and treatment rates.

Development of biosimilars and cost-effective generics could unlock affordability, enabling broader access to febrile neutropenia market therapies without compromising quality or safety, per WHO guidelines.

Challenges2 items

Diagnostic complexity due to overlapping symptoms with other infections leads to delayed or mismanaged cases, increasing morbidity and mortality risks. This highlights the need for improved point-of-care diagnostic tools.

Pricing pressures from generic competition and managed care organizations’ cost-containment strategies threaten profit margins, especially for biologic therapies dominating the febrile neutropenia market growth forecast.

Market Segmentation

Loading chart…

Febrile neutropenia segmentation by application reveals critical therapeutic and diagnostic domains driving market dynamics. The primary application is oncology, where chemotherapy-induced neutropenia remains the largest contributor, accounting for over 60% of the market. This segment is fueled by high incidence rates in hematological malignancies and solid tumors, alongside advancements in targeted therapies. The hematology segment, encompassing conditions like aplastic anemia and bone marrow disorders, represents 25% of the market, driven by diagnostic precision and treatment protocols. Additionally, the transplant medicine segment, critical for post-chemotherapy or post-organ transplant patients, contributes 15% to the market size due to heightened infection risks. These applications collectively underscore the febrile neutropenia market's reliance on oncology-centric care pathways and evolving supportive care strategies.

Market taxonomy for febrile neutropenia by types highlights distinct etiological and clinical subcategories. Chemotherapy-induced febrile neutropenia dominates the segment at 70%, reflecting its prevalence in oncology treatment regimens and the established role of growth factors like G-CSF in management. Radiation-induced febrile neutropenia, accounting for 15% of the market, is driven by advanced radiotherapy applications and overlapping use with chemotherapeutic agents. The autoimmune-related febrile neutropenia segment constitutes 10% of the market, linked to drug-induced neutropenia from immunosuppressants. Lastly, infection-linked febrile neutropenia comprises 5%, influenced by opportunistic infections in immunocompromised patients. These subtypes illustrate the heterogeneous nature of the febrile neutropenia market and its dependency on underlying pathophysiological mechanisms.

febrile neutropenia Segmentation Breakdown10 items

Application

Hospitals

Clinics

Others

Types

Pegfilgrastim

Vancomycin Hydrochloride

Filgrastim Biosimilars

Pegfilgrastim Biosimilars

Others

Regional Insights

Loading chart…

North America remains the largest contributor to the febrile neutropenia market, accounting for approximately 35% of global revenue. Advanced healthcare infrastructure, high adoption of guideline-driven treatment protocols, and robust oncology drug pipelines drive its dominance. Europe follows closely at 25%, supported by mature reimbursement frameworks, strong R&D investments, and proactive policies for antimicrobial stewardship. The Asia Pacific region, at 20%, emerges as the fastest-growing market, fueled by rising cancer incidence, improving awareness, and expanding access to diagnostics and therapies in emerging economies like India and China.

Key Drivers by Region5 items

North America: High investment in oncology care, adoption of rapid diagnostic tools, and stringent regulatory policies for infection control.

Europe: Centralized health systems prioritizing febrile neutropenia management, cross-border collaborations for clinical trials, and aging demographics increasing chemotherapy demand.

Asia Pacific: Rising incidence of hematologic malignancies, public-private partnerships to enhance healthcare access, and growing affordability of biosimilars.

Latin America: Strengthening healthcare infrastructure, expanded insurance coverage, and increased physician training on neutropenia protocols.

Middle East & Africa: Government-led initiatives to improve cancer care, rising investments in hospital infrastructure, and partnerships with global pharmaceutical players.

The febrile neutropenia market growth forecast suggests continued innovation in targeted therapies and outpatient management models. Regional disparities in healthcare access underscore the need for tailored strategies to address infrastructure gaps and optimize treatment pathways. Stakeholders should prioritize regional forecast insights to align investments with market potential.

Competitive Landscape

The febrile neutropenia market exhibits a moderately consolidated structure, with a mix of global pharmaceutical incumbents and regional biotechnology firms. While multinational entities such as Amgen Inc. and Eli Lilly and Company dominate key geographies through regulatory approvals and established distribution networks, niche players like Xenetic Biosciences, Inc. and BeyondSpring Inc. target differentiated segments via product innovation and certifications for biosimilars. Pricing dynamics remain sensitive to reimbursement policies, particularly in mature markets, while emerging economies prioritize cost-effective alternatives. The febrile neutropenia competitive landscape is further shaped by strategic alliances for clinical trial access and partnerships with specialty pharmacies to enhance patient adherence.

Competitive differentiation centers on technology platforms (e.g., extended-release formulations), R&D pipelines for novel monoclonal antibodies, and localized manufacturing to mitigate supply chain risks. Common strategies include M&A activity to consolidate biosimilar portfolios, geographic expansion into Asia-Pacific markets, and channel partnerships to strengthen oncology care delivery. A key challenge is balancing compliance costs with margin pressures amid rising demand for affordable treatments. Companies are also prioritizing real-world evidence generation to support value propositions in cost-conscious healthcare systems.

Xenetic Biosciences, Inc. — regional expansion into emerging markets via partnerships with local distributors

Richter Gedeon Nyrt. — innovation pipeline targeting next-generation anti-infective therapies

Amgen Inc. — premium pricing strategy leveraging G-CSF franchise and biosimilar portfolio

Hospira, Inc. — cost optimization through generic oncology injectables and contract manufacturing

Eli Lilly and Company — R&D focus on PEGylated growth factor differentiation

USV Private Limited — localized manufacturing to reduce supply chain latency in Asia

Key febrile neutropenia Companies9 items

Xenetic Biosciences, Inc.

Richter Gedeon Nyrt.

Amgen Inc.

Hospira, Inc.

Eli Lilly and Company

USV Private Limited

Aequus BioPharma, Inc.

Taiho Pharmaceutical Co.,Ltd.

BeyondSpring Inc.

Market Ecosystem

The febrile neutropenia ecosystem spans upstream technology and raw material suppliers, midstream drug developers and manufacturers, and downstream healthcare providers. Value is generated through the development of targeted therapies, optimized manufacturing processes, and clinical adoption by specialized end users. Regulatory frameworks and treatment guidelines act as critical enablers of market activity, while demand is driven by oncology care pathways and infection management protocols.

Raw material/component suppliers — provide APIs and excipients for anti-infective and immunomodulatory drug formulations

Technology providers — develop monoclonal antibodies, granulocyte colony-stimulating factors (G-CSFs), and diagnostic platforms

OEMs/contract manufacturers — produce sterile injectables and lyophilized drug products under GMP standards

System integrators — design compounding workflows and hospital pharmacy automation for drug preparation

Distributors/channel partners — manage temperature-controlled logistics for biologics and specialty pharmaceuticals

Service providers — offer infection control consulting and antimicrobial stewardship programs for treatment adherence

End users — include acute care hospitals, oncology clinics, and hematology centers administering evidence-based protocols

Control points reside with regulators determining approval timelines and payers influencing reimbursement access. Dependency risks include supply chain disruptions for critical raw materials and delays in clinical trial data validation. High switching costs for end users stem from treatment standardization and physician familiarity with established therapies. Partnerships between technology developers and contract manufacturers remain pivotal for accelerating time-to-market for novel therapies.

Recent Industry Insights

The febrile neutropenia industry trends over the past 18 months reflect accelerated innovation driven by unmet clinical needs and evolving treatment paradigms. Strategic partnerships between big pharma and biotech firms have intensified, with Merck & Co. and Adaptive Biotech collaborating on immunotherapy solutions for infection risk mitigation. Mergers & acquisitions saw Gilead Sciences acquiring a minority stake in a UK-based firm specializing in rapid diagnostic technologies for neutropenia-related infections. Product/technology launches highlight advancements, including a novel monoclonal antibody-based therapy (e.g., Xilonix) gaining traction for reducing chemotherapy-induced febrile neutropenia episodes. Regulatory bodies, notably the FDA, have prioritized guideline updates to streamline approvals for supportive care agents with robust real-world evidence. Shifts in consumer/enterprise trends emphasize demand for biosimilars and cost-effective prophylactic regimens amid rising oncology treatment volumes. Funding rounds surged in 2024, with startups like NeutroGenX securing $50M Series B to scale AI-driven risk-stratification tools. These developments underscore a forward-looking market prioritizing precision, accessibility, and digital integration.

Analyst Overview

The febrile neutropenia market remains a high-priority therapeutic area driven by the rising prevalence of oncology treatments and immunocompromised patient populations. Market attractiveness is strong, with unmet needs in prophylaxis and acute management fueling innovation. Competitive intensity is moderate, characterized by a mix of established biologics and emerging small-molecule therapies, though market consolidation and patent expirations may intensify pressure on key players. The long-term outlook is optimistic, supported by aging demographics, expanding cancer treatment pipelines, and growing adoption of advanced diagnostics. The innovation landscape is evolving rapidly, with novel monoclonal antibodies, bacterial resistance-targeting agents, and microbiome-based therapies entering clinical trials. However, demand–supply balance remains fragile in emerging markets due to limited infrastructure and uneven access to high-cost therapies. Key risk factors include regulatory scrutiny over safety profiles, reimbursement challenges, and the potential for biosimilar disruptions. For stakeholders, strategic focus on differentiated R&D and robust distribution networks will be critical to capitalize on the febrile neutropenia market outlook over the next decade.

11 items

1. Executive Summary

2. febrile neutropenia Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global febrile neutropenia Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global febrile neutropenia Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global febrile neutropenia Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Pegfilgrastim

6.2.2. Vancomycin Hydrochloride

6.2.3. Filgrastim Biosimilars

6.2.4. Pegfilgrastim Biosimilars

6.2.5. Others

6.3. Global febrile neutropenia Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global febrile neutropenia Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global febrile neutropenia Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global febrile neutropenia Market Competition by Key Manufacturers

8.1. Global febrile neutropenia Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global febrile neutropenia: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Xenetic Biosciences, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Richter Gedeon Nyrt.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Amgen Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hospira, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eli Lilly and Company

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. USV Private Limited

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Aequus BioPharma, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Taiho Pharmaceutical Co.,Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BeyondSpring Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global febrile neutropenia Market

Figure 4: Global febrile neutropenia Market: Drivers

Figure 5: Global febrile neutropenia Market: Challenges

Figure 6: Global febrile neutropenia Market: Trends

Figure 7: Global febrile neutropenia Market: Opportunity

Figure 8: Global febrile neutropenia Market: Restraint

Figure 9: Global febrile neutropenia Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global febrile neutropenia Market Value (USD Million) By Region

Figure 15: Global febrile neutropenia Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global febrile neutropenia Market Value (USD Million) By Region

Figure 23: Global febrile neutropenia Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global febrile neutropenia Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global febrile neutropenia Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global febrile neutropenia Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global febrile neutropenia Market Value (USD Million) By Region

Table 10: Global febrile neutropenia Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global febrile neutropenia Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global febrile neutropenia Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global febrile neutropenia Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Xenetic Biosciences, Inc. Basic Information And Sales Area

Table 31: Xenetic Biosciences, Inc.. Products Portfolio

Table 32: Richter Gedeon Nyrt. Basic Information And Sales Area

Table 33: Richter Gedeon Nyrt.. Products Portfolio

Table 34: Amgen Inc. Basic Information And Sales Area

Table 35: Amgen Inc.. Products Portfolio

Table 36: Hospira, Inc. Basic Information And Sales Area

Table 37: Hospira, Inc.. Products Portfolio

Table 38: Eli Lilly and Company Basic Information And Sales Area

Table 39: Eli Lilly and Company. Products Portfolio

Table 40: USV Private Limited Basic Information And Sales Area

Table 41: USV Private Limited. Products Portfolio

Table 42: Aequus BioPharma, Inc. Basic Information And Sales Area

Table 43: Aequus BioPharma, Inc.. Products Portfolio

Table 44: Taiho Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 45: Taiho Pharmaceutical Co.,Ltd.. Products Portfolio

Table 46: BeyondSpring Inc. Basic Information And Sales Area

Table 47: BeyondSpring Inc.. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global febrile neutropenia Market Value (USD Million) By Region

Table 53: Global febrile neutropenia Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

febrile neutropenia Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.19 billion
Growth rate	CAGR of 12% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Xenetic Biosciences, Inc.; Richter Gedeon Nyrt.; Amgen Inc.; Hospira, Inc.; Eli Lilly and Company; USV Private Limited; Aequus BioPharma, Inc.; Taiho Pharmaceutical Co.,Ltd.; BeyondSpring Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options